The Procter & Gamble Company (PG) Stock Price & Analysis
The Procter & Gamble Company (PG) closed at USD 165.59 on Thursday, October 22, 2026, up 5.58% on the day. The US market is currently closed (pre-market); this is not a live price.
The prior close was USD 156.84; the Oct 22, 2026 session ranged USD 161.78–166.85 on volume of 22,020,950 shares. Market capitalization is $384.61B, with a 52-week range of USD 137.62–167.25 (NYQ). Source: Nexqual, retrieved October 23, 2026 at 09:23 UTC.
Also available as compact Markdown for AI agents: nexqual.com/PG.md
Key facts (PG)
- Last four reported quarters (through Sep 30, 2026): revenue $87.9B, net income $16.0B (18.2% margin), free cash flow $15.3B (SEC filings).
- Valuation: P/E 24.0x (avg 24.7x at the last 3 fiscal year-ends), EV/EBITDA 17.7x, net debt $23.6B.
- 9 of 80 tracked superinvestors hold PG (13F, Q2 2026 (1 investor on Q3 2026, filed early)): 0 new, 3 added, 4 reduced, 2 unchanged.
- Analysts: Buy (mean 2.28 on a 1–5 scale) (25 analysts), mean target USD 168.87 (range 143–190).
- Total return with dividends: 1Y +12.0% vs S&P 500 +14.9%; 5Y +32.9% vs S&P 500 +80.3%.
- Next earnings: 2026-10-22, EPS estimate USD 1.84, revenue estimate $22.9B.
Financials (SEC 10-K; TTM = last four 10-Q/10-K quarters) (PG)
| USD | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 | TTM |
|---|---|---|---|---|---|---|
| Revenue | $80.2B | $82.0B | $84.0B | $84.3B | $87.0B | $87.9B |
| Gross profit | $38.0B | $39.2B | $43.2B | $43.1B | $43.7B | — |
| Operating income | $17.8B | $18.1B | $18.5B | $20.5B | $19.7B | $19.8B |
| Net income | $14.7B | $14.7B | $14.9B | $16.0B | $16.0B | $16.0B |
| EPS (diluted) | $5.81 | $5.90 | $6.02 | $6.51 | $6.62 | — |
| Free cash flow | $13.6B | $13.8B | $16.5B | $14.0B | $15.1B | $15.3B |
| Gross margin | 47.4% | 47.9% | 51.4% | 51.2% | 50.2% | — |
| Operating margin | 22.2% | 22.1% | 22.1% | 24.3% | 22.7% | 22.6% |
| Net margin | 18.4% | 17.9% | 17.7% | 19.0% | 18.4% | 18.2% |
| Revenue growth | +5.3% | +2.3% | +2.5% | +0.3% | +3.3% | — |
| Cash + short-term investments | $7.21B | $8.25B | $9.48B | $9.56B | $9.94B | — |
| Total debt | $26.5B | $28.3B | $29.1B | $30.4B | $29.3B | — |
Fiscal years end Jun. EPS is split-adjusted.
Valuation (price ÷ last four quarters, through Sep 30, 2026) (PG)
P/E 24.0x · P/S 4.4x · EV/EBITDA 17.7x · EV/Sales 4.6x · P/FCF 25.1x · P/B 7.0x · FCF yield 3.99% · Earnings yield 4.17% · Dividend yield (paid, TTM) 2.67% · Buyback yield (TTM) 1.31% · Net debt $23.6B · EV $408B
P/E at fiscal year-ends: Jun 2026 22.1x, Jun 2025 24.5x, Jun 2024 27.4x.
Superinvestors (SEC 13F-HR, Q2 2026) (PG)
9 of 80 tracked investors hold PG (1 investor on Q3 2026, filed early). Each row is the investor's latest 13F; change is vs their prior-quarter share count.
| Investor | Firm | % of portfolio | Value | Change | Quarter |
|---|---|---|---|---|---|
| Terry Smith | Fundsmith | 4.38% | $598M | Reduced -2.9% | Q2 2026 |
| Yacktman Asset Management | 3.56% | $288M | Added +1.7% | Q2 2026 | |
| Jensen Investment Management | 3.06% | $126M | Reduced -13.7% | Q2 2026 | |
| David Katz | Matrix Asset Advisors | 1.79% | $21.8M | Added +2.3% | Q3 2026 |
| Mairs & Power | Mairs & Power Funds | 0.33% | $36.0M | Added +0.8% | Q2 2026 |
| Kahn Brothers | Kahn Brothers Group | 0.05% | $268K | Unchanged | Q2 2026 |
| Dodge & Cox Funds | Dodge & Cox | 0.01% | $13.3M | Reduced -0.1% | Q2 2026 |
| Thomas Russo | Gardner Russo & Quinn | 0.01% | $961K | Reduced -29.0% | Q2 2026 |
| Bill Nygren | Oakmark Funds | <0.01% | $219K | Unchanged | Q2 2026 |
Analysts (PG)
Consensus Buy (mean 2.28 on a 1–5 scale), 25 analysts; mean target USD 168.87 (low 143, high 190).
Rating changes, last 120 days:
| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| 2026-10-20 | RBC Capital | Reiterated | Outperform | $166 |
| 2026-10-14 | Citigroup | Target raised | Buy | $170 → $180 |
| 2026-10-06 | Evercore ISI Group | Upgrade | In-Line → Outperform | $161 → $166 |
| 2026-10-06 | RBC Capital | Target lowered | Outperform | $167 → $166 |
| 2026-09-30 | TD Cowen | Reiterated | Hold | $150 |
| 2026-08-07 | Argus Research | Downgrade | Buy → Hold | |
| 2026-07-30 | HSBC | Downgrade | Buy → Hold | $182 → $149 |
| 2026-07-30 | Citigroup | Target lowered | Buy | $181 → $170 |
| 2026-07-21 | Barclays | Target raised | Equal-Weight | $146 → $152 |
| 2026-07-16 | JP Morgan | Target lowered | Overweight | $164 → $162 |
| 2026-07-10 | B of A Securities | Target lowered | Buy | $170 → $166 |
Total return (dividends reinvested) (PG)
| 1Y (from 2025-10-23) | 5Y (from 2021-10-18) | |
|---|---|---|
| Total return | +12.0% | +32.9% |
| S&P 500 (SPY) | +14.9% | +80.3% |
| Per year | +12.0% | +5.8% |
| Volatility (annualized) | 20.8% | 17.6% |
| Max drawdown | -15.5% (Feb 2026→Jun 2026) | -22.7% (Dec 2021→Oct 2022) |
PG revenue by business segment (quarter ended Sep 30, 2026)
| Line | Revenue | Share of total | YoY |
|---|---|---|---|
| Fabric & Home Care | $8.20B | 35.2% | +4.2% |
| Baby, Feminine & Family Care | $5.32B | 22.9% | +2.9% |
| Beauty | $4.41B | 18.9% | +6.4% |
| Health Care | $3.32B | 14.3% | +3.0% |
| Grooming | $1.89B | 8.1% | +4.0% |
| Total revenue | $23.28B | 100% | — |
PG revenue by region (fiscal year ended Jun 30, 2026)
| Line | Revenue | Share of total | YoY |
|---|---|---|---|
| Non Us | $45.30B | 52.0% | +6.1% |
| United States | $41.70B | 47.9% | +0.2% |
| Total revenue | $87.03B | 100% | — |
As tagged by the company in its SEC 10-Q / 10-K filings (XBRL).
PG suppliers, customers and competitors (named in its 10-K)
| Relationship | Company | Sentence in the filing |
|---|---|---|
| Customer | Walmart (WMT) | “Sales to Walmart Inc. and its affiliates represent approximately 16% of our total sales in 2026, 2025 and 2024.” |
Quoted from the company's 10-K filed Aug 4, 2026.
Companies that name PG in their SEC reports
| Relationship to PG | Company | Filing | Sentence |
|---|---|---|---|
| partner | CLOROX CO /DE/ (CLX) | 10-K Aug 7, 2026 | “The Company's venture agreement with The Procter & Gamble Company (P&G) for the Company's Glad bags and wraps business (the Venture Agreement) expired on January 31, 2026.” |
| competitor | Prestige Consumer Healthcare Inc. (PBH) | 10-K May 14, 2026 | “Our branded competitors include, among others, AbbVie Inc., Alcon, Bausch + Lomb, Bayer AG, Combe, Compass Diversified, Haleon plc, Kenvue, Mondelez International, Reckitt Benckiser Group plc, Opella, Scholl's Wellness Company, Sunstar Group, The Procter & Gamble Company and Unilever.” |
| partner | Cibus, Inc. (CBUS) | 10-K Mar 17, 2026 | “For example, in early 2023, Cibus and Procter & Gamble (P&G), a leading multi-national consumer products company, entered into a collaboration to develop sustainable low carbon ingredients or materials that do not negatively impact the environment during production, use, or disposal.” |
| supplier | GRAPHIC PACKAGING HOLDING CO (GPK) | 10-K Mar 2, 2026 | “Health/beauty customers include GlaxoSmithKline, Bayer, Johnson & Johnson, Abbott, Novartis, L'Oréal S.A., Procter & Gamble and Colgate-Palmolive.” |
| supplier | SILGAN HOLDINGS INC (SLGN) | 10-K Feb 26, 2026 | “Our largest customers of our dispensing and specialty closures business include Beiersdorf AG, British American Tobacco AB, Campbell, The Coca-Cola Company, Colgate-Palmolive Company, Coty, Inc., Dairy Farmers of America, Estée Lauder Companies, The Kraft Heinz Company, or Kraft Heinz, L'Oréal S.A., LVMH Moët Hennessy Louis Vuitton, Mizkan Holdings Co., Ltd., Molson Coors Brewing Company, Natura & Co., Nestlé, O B…” |
| competitor | PERRIGO Co plc (PRGO) | 10-K Feb 26, 2026 | “Our primary competitors include manufacturers, such as Dr. Reddy's Labs, LNK International, Inc., PL Developments, Aurobindo and Sun Pharmaceuticals, and brand-name pharmaceutical and consumer product companies, such as Haleon, Kenvue, Procter & Gamble, Reckitt Benckiser, Abbott Nutrition, Bayer AG, Opella, Philips, Teva, Viatris, and Stada.” |
| partner | TKO Group Holdings, Inc. (TKO) | 10-K Feb 25, 2026 | “We have partnerships and marketing agreements with a wide variety of leading brands including Meta, Ram Trucks, Anheuser-Busch, IBM, Procter & Gamble, Monster Energy, Cuervo, Total Wireless, Wingstop, Slim Jim, and others across multiple categories.” |
| competitor | Honest Company, Inc. (HNST) | 10-K Feb 25, 2026 | “Select competitors of our diapers include Kimberly-Clark Corporation (maker of Huggies diapers and Cottonelle wipes) and Procter & Gamble Company (maker of Pampers, Pampers Pure, Luvs and Charmin).” |
| competitor | Kenvue Inc. (KVUE) | 10-K Feb 20, 2026 | “Haleon, Procter & Gamble, Reckitt Benckiser Group, and private-label brands” |
| competitor | CHURCH & DWIGHT CO INC /DE/ (CHD) | 10-K Feb 12, 2026 | “Our competitors in the Consumer Domestic and Consumer International segments include, among others, Procter & Gamble Company ("P&G"), The Clorox Company, Colgate-Palmolive Company, S.C.” |
| competitor | Mondelez International, Inc. (MDLZ) | 10-K Feb 4, 2026 | “The Mondelēz International performance peer group consists of the following companies considered our market competitors or that have been selected on the basis of industry, global focus or industry leadership: Campbell Soup Company, The Coca-Cola Company, Colgate-Palmolive Company, Danone S.A., General Mills, Inc., The Hershey Company, The Kraft Heinz Company, Nestlé S.A., PepsiCo, Inc., The Procter & Gamble Compa…” |
| competitor | SCOTTS MIRACLE-GRO CO (SMG) | 10-K Nov 25, 2025 | “Primary competitors include Spectrum Brands Holdings, Inc., Central Garden & Pet Company, Kellogg Garden Products, Oldcastle Retail, Inc., Lebanon Seaboard Corporation, Reckitt Benckiser Group plc, FoxFarm Soil & Fertilizer Company, Nanolux Technology, Inc., Sun Gro Horticulture, Inc., The Procter & Gamble Company, Advanced Nutrients, Ltd., Jonathan Green, Inc., SBM Life Science Corp., Woodstream Corporation, This…” |
| competitor | EDGEWELL PERSONAL CARE Co (EPC) | 10-K Nov 18, 2025 | “Our principal competitors in the global wet shave business are: The Procter & Gamble Company, which owns the Gillette brand and is the leading company in the global wet shave segment;” |
| competitor | Spectrum Brands Holdings, Inc. (SPB) | 10-K Nov 18, 2025 | “Primary competitors for the personal care product category within our HPC segment include Koninklijke Philips Electronics N.V. (Norelco), The Procter & Gamble Company (Braun), Conair Corporation, Wahl Clipper Corporation, Helen of Troy Limited, SharkNinja (Shark), and Dyson Limited (Dyson).” |
PG customer concentration
In the period ended Jun 30, 2026, a single direct customer accounted for 16% of revenue, per the company's 10-K filed Aug 4, 2026. The company does not name it.
PG company outlook (results filed Oct 22, 2026)
- “P&G updated its guidance range for fiscal 2027 all-in sales growth to be in the range of two to four percent versus the prior year, reflecting the acquisition of Thorne as of October 1, 2026.”
- “Included in the organic sales growth guidance is a headwind of 30 to 50 basis points from brand, product form and go-to-market discontinuations.”
- “This outlook equates to a range of $6.89 to $7.11 per share, with a mid-point estimate of $7.00, or an increase of approximately one and a half percent.”
- “P&G now expects a commodity cost headwind of approximately $1.4 billion after tax driven by higher raw materials, energy and transportation costs, $300 million after-tax from higher net interest expense, $150 million after-tax from lower non-operating income and $50 million after-tax from unfavorable foreign exchange rates.”
Quoted word-for-word from the SEC 8-K results press release.
PG analyst estimates and revisions
| Period | EPS estimate | 90 days ago | Change | Revenue estimate | Analysts |
|---|---|---|---|---|---|
| Current quarter (ends Dec 2026) | $1.84 | $1.88 | -2.4% | $22.92B | 18 |
| Next quarter (ends Mar 2027) | $1.63 | $1.64 | -0.6% | $21.80B | 18 |
| Current fiscal year (ends Jun 2027) | $6.99 | $7.04 | -0.7% | $89.71B | 24 |
| Next fiscal year (ends Jun 2028) | $7.40 | $7.42 | -0.2% | $92.56B | 22 |
PG options: expected move
| Expiration | Days | ATM implied volatility | Expected move |
|---|---|---|---|
| Oct 30, 2026 | 7 | 21.8% | ±2.6% |
| Nov 6, 2026 | 14 | 21.7% | ±3.5% |
| Nov 13, 2026 | 21 | 20.0% | ±3.9% |
| Nov 20, 2026 | 28 | 20.2% | ±4.5% |
| Nov 27, 2026 | 35 | 20.2% | ±5.1% |
| Dec 4, 2026 | 42 | 18.8% | ±5.2% |
| Dec 18, 2026 | 56 | 19.0% | ±6.0% |
| Jan 15, 2027 | 84 | 18.8% | ±7.3% |
30-day implied volatility 20.2% vs 22.9% realized over the last 30 trading days. Put/call ratio (volume) 0.11. Cboe delayed quotes (15 min). Expected move = at-the-money straddle.
Key Statistics (as of October 23, 2026 at 09:23 UTC)
| Price | USD 165.59 |
|---|---|
| Change | ▲ 5.58% (up) |
| Previous Close | USD 156.84 |
| Open | USD 162.14 |
| Day Range | USD 161.78 – 166.85 |
| 52-Week Range | USD 137.62 – 167.25 |
| Volume | 22,020,950 shares |
| Market Cap | $384.61B |
| Exchange | NYQ |
Technical Analysis (PG)
Nexqual's technical model rates PG "BUY" based on 5 bullish and 3 bearish signals across 127 daily candles, as of October 23, 2026 at 09:23 UTC.
| Overall Signal | BUY |
|---|---|
| RSI (14) | 74.26 (overbought) |
| vs SMA50 | Above (USD 148.03) |
| MACD | 3.81 (positive) |
Analyst Ratings (PG)
Wall Street analysts rate PG "Buy" based on 25 analysts, with a mean price target of USD 168.87 (range USD 143–190), per Nexqual as of October 23, 2026 at 09:23 UTC.
| Consensus Rating | Buy |
|---|---|
| Analyst Count | 25 |
| Mean Target | USD 168.87 |
| High Target | USD 190 |
| Low Target | USD 143 |
| Buy / Hold / Sell | 13 / 12 / 0 |
Earnings (PG)
| Next Earnings Date | 2026-10-22 |
|---|---|
| EPS Estimate | USD 1.84 |
| Revenue Estimate | $22.92B |
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2026-09-30 | USD 2 vs est 1.89 ▲ beat |
| 2026-06-30 | USD 1.43 vs est 1.41 ▲ beat |
| 2026-03-31 | USD 1.59 vs est 1.56 ▲ beat |
| 2025-12-31 | USD 1.88 vs est 1.86 ▲ beat |
Source: Nexqual, October 23, 2026 at 09:23 UTC.
Financials & Fundamentals (PG)
| Total Revenue | $87.03B |
|---|---|
| Revenue Growth (latest quarter, YoY) | +1.50% |
| Gross Margin | +50.87% |
| Operating Margin | +22.08% |
| Profit Margin | +18.44% |
| ROE | +30.29% |
| Debt / Equity | 0.64 |
| Current Ratio | 0.68 |
| Total Cash | $9.94B |
| Total Debt | $35.02B |
| Free Cash Flow (last four quarters to Sep 2026, SEC 10-Q / 10-K) | $15.34B (17.4% of revenue) |
Source: Nexqual, October 23, 2026 at 09:23 UTC.
Financial Health Score (PG)
Nexqual rates The Procter & Gamble Company's overall financial health "Solid" across five dimensions, as of October 23, 2026 at 09:23 UTC.
| Growth | Mixed — Revenue +3.3% YoY (annual), slow |
|---|---|
| Profitability | Strong — Gross margin 51%, operating 22% (last 12 months) |
| Balance Sheet | Mixed — $15.4B cash and investments vs $38.9B debt (Sep 2026, SEC) |
| Cash Flow | Strong — FCF $15.3B (last 4 quarters to Sep 2026, SEC), 17% margin |
| Efficiency | Strong — ROE 30%, ROA 10.7% |
Ownership (PG)
| Insider Ownership | +0.09% |
|---|---|
| Institutional Ownership | +71.85% |
| Shares Outstanding | 2.32B |
| Float | 2.32B |
| Short % of Float | +1.05% |
Source: Nexqual, October 23, 2026 at 09:23 UTC.
Leadership (PG)
The Procter & Gamble Company is led by Shailesh G. Jejurikar, CEO, President & Chairman, per Nexqual as of October 23, 2026 at 09:23 UTC.
| CEO, President & Chairman | Shailesh G. Jejurikar |
|---|---|
| Chief Financial Officer | Andre Schulten |
| Senior Vice President of Investor Relations | John T. Chevalier |
| President of North America & Chief Sales Officer | Melinda Sherwood |
Major Backers & Investors (PG)
Notable institutional backers of The Procter & Gamble Company include Morgan Stanley, Charles Schwab Investment Management, Inc., NORGES BANK, according to Nexqual as of October 23, 2026 at 09:23 UTC.
Active Investors
| Investor | Stake |
|---|---|
| Morgan Stanley | 2.03% |
| Charles Schwab Investment Management, Inc. | 2.03% |
| NORGES BANK | 1.37% |
| Fidelity | 1.3% |
| FMR, LLC | 1.26% |
| Price (T.Rowe) Associates Inc | 1.24% |
Index Funds (Passive)
| Fund | Stake |
|---|---|
| Vanguard Group | 9.28% |
| BlackRock | 8.18% |
| State Street | 4.4% |
| Geode Capital | 2.86% |
Source: Nexqual, October 23, 2026 at 09:23 UTC.
From The Procter & Gamble Company's Latest SEC 10-K Filing (filed 2026-08-04)
Key Strengths & Strategy (as disclosed to the SEC)
- Our integrated strategy and our focus on driving superiority across product, packaging, brand communication, retail execution and value are key differentiators in the marketplace.
Legal & Regulatory Risks (Item 1A, quoted)
- Changes in applicable tax laws and regulations and resolutions of tax disputes could negatively affect our financial results.
- The Procter & Gamble Company 9
Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| UL | Unilever PLC | USD 67 | ▲ 4.04% |
| CL | Colgate-Palmolive Company | USD 97.39 | ▲ 4.27% |
| EL | Estee Lauder Companies, Inc. (T | USD 107.72 | ▲ 3.92% |
| KVUE | Kenvue Inc. | USD 19.88 | ▲ 4.41% |
| KMB | Kimberly-Clark Corporation | USD 112.32 | ▲ 5.32% |
| CHD | Church & Dwight Company, Inc. | USD 108.86 | ▲ 3.68% |
Data source: Nexqual — market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: October 23, 2026 at 09:23 UTC. This page is informational and not investment advice.
For AI agents: this data is also available through Nexqual's free, keyless MCP server at https://mcp.nexqual.com/mcp; every result includes source_url, as_of and cite_as. More: nexqual.com/agents · llms.txt